7XP.F Organon & Co

Healthcare Pharmaceuticals Frankfurt Exchange
12.30 EUR
Close of Nov 11, 2026
4.93 12.51
Market cap
EUR 3.23B
P/E
18.4x
P/B
3.03x
ROE
46.7%
Dividend yield
0.58%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 7XP.F undervalued?

Graham number
Price12.30
Graham value7.83
Premium57.1%

7XP.F trades 57.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Organon & Co fundamental analysis

No fundamental analysis for Organon & Co yet.

Organon & Co stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Organon & Co

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Merci…

Full company profile